



# NASS VALLEY GATEWAY Ltd.

Trading Symbols

CSE: NVG

Deutsche Borse, Frankfurt: 3NVN

Germany: WKN A1JVHM/

ISIN CA6315202029

[www.nassvalleygateway.com](http://www.nassvalleygateway.com)

---

## NEWS RELEASE

### NASS VALLEY GATEWAY LTD. - CORPORATE UPDATE

Vancouver, BC, Canada – December 14, 2018

**NASS VALLEY GATEWAY LTD. (the “Company” or “Nass Valley”)** wishes to announce that at its Annual General Meeting (the “AGM”) held on Wednesday, December 12, 2018, Messrs. Milo Filgas, Eric Peter-Kaiser, Andrew von Kursell, and Dieter Peter, were re-elected as Directors of Nass Valley. Mr. James Elliott was elected as additional Member of the Company’s Board of Directors. The shareholders also re-appointed Manning Elliott LLP, Chartered Accountants as the Company’s auditors and passed the resolutions approving and ratifying the Company’s stock option plan, which is a rolling 10% plan.

Nass Valley welcomes Mr. Elliott to the Board of Directors. With his experience in senior roles as Chief Executive and Technology Officer, Principal Engineer, Special Project Engineer and his expertise in CBD extraction, Medical Devices, Diagnostics and IVD sectors he will contribute in a very proactive way to the Company’s success subsequent to the closing of its proposed transaction.

The Board of Directors appointed the following officers and committee members:

#### Officers

President & CEO

Dieter Peter

Interim Chief Financial Officer and Corporate Secretary

Eric Peter-Kaiser

#### Audit Committee

Andrew von Kursell, James Elliott, and Milo Filgas;

#### Advisory Committee

Members to be nominated during the ensuing year.

The Board decided not to establish any other board committees until it has received the final approval from the CSE for their proposed transaction for the acquisition of “Advanced Bioceuticals Limited” and “Pro-Thotics Technology Inc”.

**WE SEEK SAFE HARBOUR..**

For further information please contact:

Dieter Peter, President & CEO

Phone: 604-617-6794

Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.